Trientine hydrochloride is N,N' -bis (2-aminoethyl)-1,2-ethanediamine dihydrochloride. Trientine hydrochloride is a chelating compound for removal of excess copper from the body. SYPRINE (Trientine Hydrochloride) is available as 250 mg capsules for oral administration.
SYPRINE is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with SYPRINE is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. SYPRINE and penicillamine cannot be considered interchangeable. SYPRINE should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.
Unlike penicillamine, SYPRINE is not recommended in cystinuria or rheumatoid arthritis. The absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, SYPRINE was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment.
SYPRINE is not indicated for treatment of biliary cirrhosis.
Media Articles Related to Syprine (Trientine)
CHMP Backs Orphan Hybrid Drug for Wilson's Disease
Source: Medscape Family Medicine Headlines [2017.04.25]
Trientine tetrahydrochloride (Cuprior) is indicated for treatment of Wilson's disease in adults, adolescents, and children aged 5 years and older who are intolerant to D-penicillamine.
Published Studies Related to Syprine (Trientine)
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. [2006.04]
OBJECTIVE: To compare tetrathiomolybdate and trientine in treating patients with the neurologic presentation of Wilson disease for the frequency of neurologic worsening, adverse effects, and degree of neurologic recovery... CONCLUSION: Tetrathiomolybdate is a better choice than trientine for preserving neurologic function in patients who present with neurologic disease.
Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy. [2004.06]
We administered trientine hydrochloride, a drug used in the treatment of Wilson's disease, to patients with hepatocellular carcinoma after radical treatment with percutaneous ethanol injection or radiofrequency ablation, and examined its effect on the reduction of liver-tissue copper content... In patients with hepatocellular carcinoma, trientine hydrochloride therapy may significantly reduce copper content in liver tissue.
Evaluation of Cuprimine(R) and Syprine(R) for decorporation of radioisotopes of cesium, cobalt, iridium and strontium. [2011.08]
Cuprimine(R) and Syprine(R) are therapeutics approved by the USFDA to treat copper overload in Wilson Disease (a genetic defect in copper transport) by chelation and accelerated excretion of internally-deposited copper... Based on these encouraging findings, further studies to evaluate the dose-response profiles and timing of the chelator administration post exposure to radionuclides are warranted.
Evaluation of Cuprimine and Syprine for decorporation of (60)Co and (210)Po. [2010.03]
The acknowledged risk of deliberate release of radionuclides into local environments by terrorist activities has prompted a drive to improve novel materials and methods for removing internally deposited radionuclides. These decorporation treatments will also benefit workers in the nuclear industry, should an exposure occur.
Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature. [2009.09]
Our aim was to review our experience of trientine as chelation therapy in children with Wilson disease (WD) and compare to that reported in the literature. We made a retrospective review of the medical notes of 16 of 96 (17%) children diagnosed with WD between 1981 and 2006... Whilst the current evidence is low quality, it appears that trientine is as efficacious as penicillamine and small population studies show a lower side effect profile.
Clinical Trials Related to Syprine (Trientine)
Trientine and Carboplatin in Advanced Malignancies [Completed]
The goal of this clinical research study is to find the highest tolerable dose of the
combination of trientine and carboplatin that can be given to patients with advanced cancer.
The safety of this drug combination will also be studied.
Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus [Not yet recruiting]
The primary purpose of the protocol is to evaluate whether Trientine Hydrochloride, a copper
chelator which is an agent that binds with and removes copper, will be effective in
minimizing macular edema after cataract surgery in individuals with type 2 diabetes. It is
our hypothesis that there will be a reduction in copper-attributed inflammation after
surgery resulting a decrease in edema.
Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy [Terminated]
To evaluate the effects of Trientine Hydrochloride in prevention of post-laser (pan-retinal
photocoagulation) macular edema in the eyes for subjects with diabetic retinopathy.
Trientine hydrochloride can limit secondary inflammatory damage to retinal vessels following
the administration of pan-retinal photocoagulation therapy for severe non-proliferative
diabetic retinopathy or retinal neovascularization due to diabetic retinopathy, resulting in
less macular edema and improved visual outcomes.
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma [Active, not recruiting]
The purpose of this study is to evaluate the safety of combination therapy with vemurafenib
and trientine in patients with BRAF mutated metastatic melanoma.
Vemurafenib is a drug that is currently approved by the United States Food and Drug
Administration (FDA) and by the European Medicines Agency (EMA) to treat adult patients with
melanoma that has spread to other parts of the body or cannot be removed by surgery. It can
only be used in patients whose cancer has a change (mutation) in the "BRAF" gene.
Preclinical data suggests that use of a copper chelator (reducer) is a strategy to block
cellular signaling activity which would result in anti-tumor effects (slow tumor growth).
Trientine is a copper chelator and is FDA approved for the treatment of Wilson's disease (a
disease of copper metabolism) and is generally well tolerated. It works by binding to copper
to help remove it from the body. Trientine is not FDA approved for the treatment of
melanoma and its use in this study is investigational. "Investigational" means the study
drug is still being tested in research studies.
All patients will receive vemurafenib at 960mg PO twice daily with continuous dosing in
combination with trientine in escalating doses. The dose of trientine will depend on what
portion of the study.
In order to participate in the study, patients must test positive for the change (mutation)
in the BRAF gene.
Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine [Not yet recruiting]
A study to review Wilson disease patients who have previously been prescribed d-
Penicillamine but were changed to trientine as treatment for their disease, and to follow
them for a further 12 months.